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Background—Recombinant adenovirus serotype 5 (rAd5)-vectored HIV-1 vaccines have not 
prevented HIV-1 infection or disease and pre-existing Ad5 neutralizing antibodies may limit the 
clinical utility of Ad5 vectors globally. Using a rare Ad serotype vector, such as Ad35, may 
circumvent these issues, but there are few data on the safety and immunogenicity of rAd35 
directly compared to rAd5 following human vaccination.
Methods—HVTN 077 randomized 192 healthy, HIV-uninfected participants into one of four 
HIV-1 vaccine/placebo groups: rAd35/rAd5, DNA/rAd5, and DNA/rAd35 in Ad5-seronegative 
persons; and DNA/rAd35 in Ad5-seropositive persons. All vaccines encoded the HIV-1 EnvA 
antigen. Antibody and T-cell responses were measured 4 weeks post boost immunization.
Results—All vaccines were generally well tolerated and similarly immunogenic. As compared to 
rAd5, rAd35 was equally potent in boosting HIV-1-specific humoral and cellular immunity and 
responses were not significantly attenuated in those with baseline Ad5 seropositivity. Like DNA, 
rAd35 efficiently primed rAd5 boosting. All vaccine regimens tested elicited cross-clade antibody 
responses, including Env V1/V2-specific IgG responses.
Conclusions—Vaccine antigen delivery by rAd35 is well-tolerated and immunogenic as a prime 
to rAd5 immunization and as a boost to prior DNA immunization with the homologous insert. 
Further development of rAd35-vectored prime-boost vaccine regimens is warranted.
Keywords
HIV Vaccine; Adenovirus 35; Adenovirus 5; DNA vaccine; Randomized clinical trial
Introduction
The development of a safe and effective preventive HIV vaccine remains an urgent public 
health priority in the setting of an estimated 2.1 million new infections globally [1]. Since 
the first preventive HIV vaccine candidate entered clinical testing in 1987, four distinct 
vaccine concepts including subunit protein, DNA, and viral vector vaccines have been 
evaluated in six completed efficacy trials [2-7]. Thus far, only one vaccine regimen, a 
canarypox vector encoding three HIV-1 genes with a gp120 subunit boost, demonstrated 
partial efficacy in a phase 2b study [6]. Subsequent findings indicated that non-neutralizing 
IgG antibody responses to HIV-1 Env V1/V2 were significantly correlated with decreased 
risk of infection in vaccines [8].
HIV vaccine candidates using recombinant adenovirus (rAd) vectors have been some of the 
most immunogenic [9]. The Step study (HIV Vaccine Trials Network [HVTN] 502) was the 
first efficacy trial to test an rAd5-vectored vaccine expressing HIV-1 clade B Gag, Pol and 
Nef; however the product failed to protect against infection or disease progression. 
Furthermore, this study suggested that pre-existing Ad5 neutralizing antibodies may have 
played a role in increased HIV susceptibility among vaccinees [4,10]. A multiclade/
multigene DNA prime, rAd5 boost regimen encoding HIV-1 Gag, Pol, and Nef from clade 
B, and Env from clades A, B, and C developed by the NIAID Vaccine Research Center 
(VRC) was immunogenic in early phase trials [11,12]. However, the recent HVTN 505 
phase 2b trial (NCT00865566) evaluating this regimen failed to show reduced HIV 
acquisition or viral load setpoint in Ad5-seronegative, circumcised men who have sex with 
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men and transgender women from the United States [7]. Even if such a vaccine were shown 
effective in this targeted population, preexisting neutralizing antibodies to Ad5 globally are 
highly prevalent, particularly in the developing world [13-16]. Thus, an Ad5-based HIV 
vaccine would have limited clinical utility in many of the settings where an HIV vaccine is 
needed the most.
While replication-defective rAd5-based products are unlikely to move forward as candidate 
HIV vaccines, substantial interest remains in evaluating potentially less common adenoviral 
serotype vectors, such as Ad26 and Ad35. For example, compared to Ad5, Ad35 has a 
relatively low global seroprevalence [13,14,16] and unique tropism [17] that offer the 
potential to circumvent pre-existing immunity and confer protection against infection as 
seen in non-human primate studies [18]. Consequently, Ad35 serves as the viral vector for 
several vaccine candidates to prevent HIV [19], tuberculosis [20], and hepatitis C virus 
infections [21].
The VRC developed an experimental HIV-1 Env clade A-expressing recombinant Ad35 
(rAd35) vaccine which was well tolerated and immunogenic in a phase I trial [22]. 
Compared to three DNA immunizations, a single rAd35 priming immunization would 
reduce the number of injections required, supporting greater acceptability and uptake if 
shown effective and licensed for use. Animal models suggest that Ad35 is not cross-
neutralized by antibodies to Ad5 [15,23] and that Ad35-vectored vaccines retain their 
immunogenicity in the setting of pre-existing Ad5 neutralizing antibodies [23]. However, it 
is unknown whether these observations extend to humans. The HVTN conducted a phase Ib 
study to further evaluate the safety of the VRC prototype rAd35-vectored HIV vaccine, and 
to 1) compare the HIV-specific immune responses elicited by a heterologous vector regimen 
(rAd35 prime/rAd5 boost) versus a DNA prime, rAd5 boost regimen; 2) to determine 
whether rAd35 is as potent as rAd5 as a boost following DNA priming; and 3) to assess 
whether pre-existing Ad5 neutralizing antibodies affect the HIV-specific immune responses 
to the rAd35-delivered EnvA antigen.
Subjects, Materials and Methods
Vaccines
All vaccines tested in HVTN 077 were produced by the NIH VRC and GenVec, Inc. 
(Gaithersburg, Maryland). One prototype vaccine consisted of a single E1-deleted, 
replication-deficient group B rAd35 vector, constructed to express a truncated modified 
HIV-1 clade A Env. The full E1, E3 and partial E4 deleted replication-deficient recombinant 
group C Ad5 vector also expressed the same truncated modified version of the HIV-1 clade 
A env gene. Both vaccines were formulated at a dose of 1 × 1010 particle units and 
administered by needle and syringe intramuscularly.
The DNA-EnvA vaccine encodes for the clade A env gene and is one of the 6 plasmids 
included in HVTN 505 regimen [7]. The DNA vaccination was administered 
intramuscularly via the needle free injection device Biojector® 2000 (Tualitin, Oregon) at a 
dose of 4mg. The placebos for the adenovectors and DNA vaccines were final formulation 
buffer and phosphate-buffered saline (PBS), respectively.
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Study design and procedures
HVTN 077 was a randomized, double-blind, placebo-controlled phase 1b trial conducted at 
11 clinical sites in the United States. The protocol was approved by the institutional review 
boards of all participating centers (Clinical Trials.gov registration NCT00801697). Between 
February of 2009 and January 2010, 192 adults aged 18-50 who reported low risk for 
infection and determined to be HIV-1-seronegative and healthy based on medical history, 
physical exam, and laboratory tests were enrolled after providing written informed consent. 
Eligible individuals who consented and enrolled were randomized to one of four treatment 
(T) groups (Table 1). Individuals randomized to treatment groups 2 (DNA/rAd5) or 3 
(DNA/rAd35) were blinded to their assignment. For all groups, participants were blinded to 
assignment to vaccine or placebo. All participants were Ad35 neutralizing antibody (nAb) 
negative at baseline; for groups 1-3, participants were also Ad5 nAb negative. In group 4, 
participants were Ad5 nAb positive determined by nAb titers ≥ 18.
Safety evaluations included physical examinations and standard clinical chemistry and 
hematological tests. Local injection site (pain, tenderness, redness, erythema, and 
induration) and systemic (malaise, headache, fever, chills, myalgias, arthralgias, nausea, 
vomiting, and fatigue) reactogenicity symptoms were assessed for three days following each 
vaccination or until resolution. Adverse events were graded based on the HVTN Table for 
Grading Severity of Adverse Experiences (http://rsc.tech-res.com/Document/
safetyandpharmacovigilance/
Table_For_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf). Several licensed 
diagnostic HIV ELISA assays (Abbott HIVAB HIV 1/2 [rDNA], Abbott Architect HIV 
Ag/Ab Combo, BioRad Genetic System HIV 1/2 Plus O EIA, BioRad Genetic System HIV 
1/2 rLAV, and BioRad Multispot HIV-1/HIV-2 Rapid Test) were performed on sera on all 
participants at the end of study (Day 364) to assess vaccine-induced seroreactivity.
Blood samples for assessment for primary immunogenicity were collected at days 28 (4 
weeks after the single rAd35 priming injection in Group 1), 84 (4 weeks after the DNA 
priming series in Groups 2-4) and 196 (4 weeks after the boost vaccination in all groups).
Immune response assays
Humoral responses
Neutralizing Antibodies to Ad5 and Ad35: Baseline Ad5 neutralizing antibody titers were 
measured as previously described with titers ≥ 18 noted as positive [24]. Ad35 neutralizing 
antibody titers were measured by luciferase transgene detection [25], and titers ≥ 12 noted as 
positive.
HIV-Specific Binding Antibody Assays: Validated binding antibody multiplex assays [26] 
for measurement of vaccine elicited HIV-1 Envelope-specific IgG to Group M Consensus 
(Con S gp140 CFI), Clade A (00MSA 4076 gp140), Clade B (B.con.env03 140 CF), and 
Clade C (C.con.env03 140 CF) were performed according to a pre-specified assay study 
plan following GCLP guidelines. Additional studies were performed for Env V1V2 reactive 
antibodies [8] utilizing scaffolds gp70 V1V2 VRC EnvA [27] and gp70 V1V2 (Case A2) 
[28]. HIV-1-specific IgG was detected from 1:50 serum dilution with biotinconjugated 
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mouse anti-human IgG (Southern Biotech, Birmingham, AL) (4 μg/ml), followed by 
washing and incubation with streptavidin-PE (BD Pharmingen). Mean fluorescent intensity 
(MFI) readouts were acquired on a Bio-Plex instrument (BioRad). Positive controls (purified 
HIV-1 positive immunoglobulin [HIVIG] and CH58 mAb [27] for the V1V2 assays) and 
negative controls (blank beads, HIV-1 negative sample, and baseline samples) were included 
to ensure specificity and for maintaining consistency and reproducibility between assays.
Positivity of antibody binding at Day 196 was defined by meeting all three conditions: (1) 
the MFI minus blank values are ≥ antigen specific cutoff (based on the average + 3 standard 
deviations of 80 seronegative plasma samples), (2) the MFI minus blank values are greater 
than 3 times the baseline (Day 0) MFI minus blank values, and (3) the MFI values are 
greater than three times the baseline MFI values. For positive responses, binding magnitude 
was quantified by the net MFI concentration (subtracting the blank value) estimated using a 
10-point standard curve (4PL fit).
T Cell Response: Peripheral blood mononuclear cells (PBMC) were isolated and 
cryopreserved from whole blood within 8 hours of venipuncture using standard procedures 
[29]. A 10-color intracellular cytokine staining (ICS) assay was performed on cryopreserved 
PBMC as previously described [30-32]. For the detection of HIV-specific T cells, thawed 
PBMC were rested overnight and then stimulated for 6 hours with overlapping HIV-1 15-
mer peptide pools matched to the vaccine insert (VRC EnvA). Positivity was established at 
p<10−5 using a Fisher's exact test comparing stimulated and unstimulated samples.
Statistical analysis
All data from enrolled participants who received at least one vaccination were analyzed. 
Five study groups were evaluated for immunogenicity: the four vaccinated groups 
individually plus the pooled placebo groups. HIV-1 specific IgG binding antibody and T-cell 
responses were evaluated at baseline (Day 0, IgG only) and at the primary immunogenicity 
timepoint, Day 196 (one month after the final injection). Rates of HIV-1 Env-specific 
antibodies and positive CD4+ and CD8+ T-cell responses (for cells expressing IFN-γ and/or 
IL-2 as measured by ICS) were estimated for each study group and timepoint. Lachenbruch's 
test was used for comparing primary immunogenicity endpoints between study groups [33]. 
Response rates were compared between groups using Fisher's exact tests. Magnitudes of 
responses among positive responders were compared between study groups using Wilcoxon 
rank sum tests. All statistical tests were 2-sided. Primary and secondary analyses comparing 
immunogenicity endpoints between vaccinated groups were considered statistically 
significant if p ≤ 0.033, chosen to control the overall type I error rate at 0.10 and correcting 
for three pairwise comparisons. All other analyses used p ≤ 0.05 to judge statistical 
significance. All descriptive and inferential statistical analyses were performed using SAS 
and/or R statistical software.
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Results
Participant accrual, demographic data, and vaccine safety
Of the 736 individuals who underwent screening procedures, 40.3% had detectable 
neutralizing antibodies to Ad5 whereas only 9% were Ad35 seropositive (Table 2). The 
median age of the 192 enrolled participants was 28 years; 42% were women, 65% were non-
Hispanic whites, 8% were Hispanic, and 16% Non-Hispanic Black. All participants received 
their initial vaccination and 98% received the second vaccination; of those assigned to 4 
injections, 94% received the third, and 90% all four vaccinations. No significant differences 
were observed in vaccine completion rates between treatment groups. The primary reasons 
for study discontinuation included loss to follow-up or participant relocation (n= 9), 
incarceration (n =1), refusal (n =2) or other reasons (n =2); none were due to adverse 
experiences or reactogenicity related to vaccination.
Overall, each of the vaccine components was well tolerated. Pain/and or tenderness at the 
injection site was reported most commonly (88% of study participants). Differences between 
groups were detected; as seen in Figure 1, those receiving the rAd35/rAd5 heterologous 
adenovector regimen were less likely to report local reactions compared to the DNA prime, 
adenovector boost regimens (p<0.001). Maximum systemic symptoms were less commonly 
reported by those with pre-existing neutralizing antibodies to Ad5 (T4, Figure 1). There 
were 22 adverse events that were at least probably or definitely attributed to the vaccine, and 
most were local injection site reactions that were characterized as mild or moderate in 
severity. One case of transient mild leukopenia deemed probably related to vaccination was 
observed after receiving DNA in a T4 participant. Four expedited adverse events were 
reported in the trial including rectal bleeding, post traumatic lower extremity and right 
intraorbital ethmoid fractures, bipolar disorder, and gallstone pancreatitis; none were 
attributed to product. No significant differences in laboratory parameters were noted among 
groups. Overall, 60% had evidence of vaccine-induced HIV seroreactivity at the end of 
study using several commercially available HIV test kits. Rates were highest among rAd35/
rAd5 vaccinees (81.8%) and lowest among participants who received DNA/rAd5 (45.7%).
HIV-1–specific antibody responses
Each of the vaccine regimens induced high frequency and magnitude cross-clade binding 
antibody responses (Figure 2). The antibody response rates were 100% for all treatment 
groups recognizing the consensus M gp140 (data not shown) and 97-100% recognizing the 
clade A Env antigen. For the clade B antigen, responses were also detected in greater than 
92% of individuals. For the clade C antigen, response frequencies were highest for rAd35/
rAd5 (96%) compared to the DNA prime/adenovector boost groups (76-78% for groups 
2-4), however at lower magnitude in comparison to the DNA/rAd5 group (p=0.02).
Based on evidence that IgG binding antibodies to V1/V2 were correlated with reduced risk 
of HIV infection in the RV144 vaccine efficacy trial [8], we explored whether the EnvA 
constructs tested in HVTN 077 elicited these responses. Among positive responders, all 
treatment groups elicited gp70V1/V2 responses using the V1/V2 scaffold tested in the 
RV144 study (Case A2, Figure 3A) and there were no significant differences by group in the 
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magnitude or frequency of the responses. In addition, we looked at the matching clade A 
V1/V2 sequence in the HVTN 077 vaccine regimen (clade A gp70V1/V2). Although the 
frequency of response did not differ substantially by group, as seen in Figure 3B, the 
response magnitude for binding antibodies to the vaccine-matched clade A gp70V1/V2 was 
significantly higher among the DNA/rAd5 group compared to the rAd35/rAd5 group, 
(p=0.005).
HIV-1–specific T-cell responses
As seen in Figure 4, HIV-1-specific T cells producing IFN-γ and/ or IL-2 in response to 
vaccine insert-matched peptides were detected readily in each of the treatment groups. With 
regard to the CD4+ T-cell responses, the highest post-boost response rates were seen among 
Ad5 seronegative individuals receiving DNA/rAd35 (25/36, 69.4%) and lowest among those 
receiving rAd35/rAd5 (9/24, 37.5%); responses did not differ significantly across groups. 
Vaccine-induced CD8+ T-cell responses were elicited most frequently among Ad5 
seronegative individuals who received the DNA/rAd5 regimen (32/42, 76.2%) and least 
among Ad5 seropositives who received the DNA/rAd35 regimen (10/25, 40.0%); responses 
did not differ significantly across groups. Overall, we found that among Ad5 seronegative 
subjects, 15%, 39%, and 32% of rAd35/rAd5, DNA/rAd5, and DNA/rAd35 recipients, 
respectively, and 14% of Ad5 seropositive participants receiving the DNA/rAd5 regimen 
developed both CD4+ and CD8+ T-cell responses. The HIV-specific CD4+ or CD8+ T-cell 
response magnitudes for positive responders after boosting were similar across groups.
In addition, we assessed expression of TNF-α and Granzyme B (GzB) in response to 
stimulation with insert-matched peptides. As shown in Figure 5, priming with DNA 
followed by either rAd35 or rAd5 led to the induction of significantly more polyfunctional 
CD4+ T cells than vaccination with rAd35/rAd5 in Ad5 seronegative subjects (p=0.0005 for 
three and p=0.007 for four functions, respectively, comparing the combined DNA/rAd5 and 
DNA/rAd35 groups with rAd35/rAd5 for Ad5 seronegative subjects). Interestingly, the 
patterns of combined expression of these functional markers did not differ significantly 
between these groups after correction for multiple comparisons (Supplementary Figure 1). 
While around 90% of HIV-specific CD8+ T cells were polyfunctional (Figure 5), only 
minor differences in expression patterns were observed among the different groups (Figure 5 
and Supplementary Figure 1).
Discussion
In this clinical study of a prototype rAd35 vectored HIV-1 vaccine, we found that it was 
well tolerated with a similar safety profile to that of rAd5-based experimental vaccines 
[12,34]. We sought to explore how the immunogenicity of the heterologous rAd35/ rAd5 
regimen compared to a DNA/rAd5 regimen, and found that rAd35/rAd5 elicited similar 
frequency and magnitude of HIV-1–specific antibody responses, and slightly (although not 
statistically significant) lower T cell responses. In addition, we found that as a boost in 
DNA-primed subjects, there were no significant differences between rAd35 and rAd5 in the 
ability to induce EnvA-specific antibody and T-cell responses. We also observed that in the 
setting of pre-existing Ad5 nAbs, there was no significant reduction of HIV-1 specific 
Fuchs et al. Page 7
J AIDS Clin Res. Author manuscript; available in PMC 2015 November 17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
antibody or cellular responses to an Ad35-based regimen when given once as a boost. This 
confirms findings from preclinical models that cross-reactive immune responses from these 
serologically distinct adenoviruses are unable to substantially dampen immunogenicity [23]. 
Finally, we found that each of the vaccine regimens tested in this trial was capable of 
inducing cross-clade binding antibodies as well as V1/V2-specific IgG antibodies, which 
were correlated with reduced risk of HIV infection in the RV144 vaccine efficacy trial [8].
The HVTN 505 Phase IIb efficacy trial showed that a DNA/rAd5 prime-boost regimen 
encoding EnvA, EnvB, EnvC, clade B Gag, Pol, and Nef was unable to prevent HIV 
acquisition or reduce viral load [7]. Of note, in HVTN 077, we found the proportion of 
vaccinees with V1/V2 IgG responses (52% to 66% across the four groups) was similar to the 
rate observed for the partially efficacious ALVAC/gp120 vaccine regimen tested in the 
RV144 trial (64%, 95% CI 58% to 70%) [8] and higher than the 17.5% rate of response 
elicited by the HVTN 505 regimen [7]. In addition, the V1/V2 IgG responses were similar 
between groups 2 and 3 (DNA/rAd5 and DNA/Ad35 in Ad5 seronegative subjects), and 
group 4 (DNA/rAd35 in Ad5 seropositive subjects). This is in contrast to findings from the 
phase 2 study of the VRC multiclade DNA/rAd5 regimen [12], where V1/V2 IgG responses 
were significantly lower in Ad5 seropositive vaccines compared to Ad5 seronegative 
individuals (G. Tomaras, personal communication). These findings suggest that presentation 
of the EnvA antigen alone may produce a more favorable antibody response to the V1/V2 
region than presentation of multiple Env proteins with additional competing antigens. It is 
important to note that we do not know if the V1/V2 IgG correlate of risk translates into a 
correlate of protection, and, if so, whether it is a mechanistic or nonmechanistic correlate 
[35] or whether IgG V1/V2 responses will be a correlate of HIV-1 risk or protection for 
vaccines in other populations that differ from the community-based sample evaluated in 
Thailand [6]. However, studies in non-human primate models suggest that envelope binding 
antibodies, V2-specific antibodies, and the avidity to which anti-Env antibodies bind to 
native trimer [18,36-38] can correlate with protection. Therefore, future HIV-1 vaccines 
designed to elicit Env binding responses and V2-specific IgG antibodies, should consider 
these observations from preclinical studies and recent clinical trials.
Whether multi-dose DNA priming for an adenovector boost confers an immunologic 
advantage over heterologous adenovector regimens is relevant given the desire for less 
complex vaccine regimens with fewer required immunizations. Compared to rAd35/rAd5, 
we found that the DNA/rAd5 regimen elicited higher magnitude binding antibody responses 
to some of the antigens tested (e.g., the EnvA clade-matched V1/V2 expressed by the 
vaccine and EnvC) but not to others (e.g, the Clade A Env). And while there was no overall 
difference in the HIV-specific CD4+ or CD8+ T-cell responses elicited by these regimens, 
DNA priming may generate more polyfunctional responses than the heterologous 
adenovector prime-boost regimen, a desirable feature of vaccines designed to elicit cellular 
immunity [39,40]. Several studies in the field will provide further insights into the relative 
immunogenicity of prime-boost regimens combining different adenovectors such as Ad35 
and Ad26 encoding an EnvA antigen (IAVI B003-IPCAVD004-HVTN091, NCT01215149) 
and DNA administered by electroporation with a multi-antigen rAd35 construct (IAVIB004; 
NCT01496989). Furthermore, to optimize immunogenicity, trials should carefully consider 
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the administration interval between adenovector prime and boost. Our study delivered 
rAd35 and rAd5 6 months apart, eliciting higher magnitude HIV-specific T-cell responses 
compared to rAd35/ rAd5 given only 3 months apart in VRC 012 (NCT00479999) [22].
Conclusion
In this phase 1b study, we have demonstrated that rAd35 is well tolerated and immunogenic, 
and as a boost, is as potent as rAd5 in DNA primed individuals. In addition, the humoral and 
cellular responses elicited by rAd35 boosting are better preserved in the setting of 
preexisting Ad5 seropositivity than responses to rAd5 boosting, suggesting that rAd35 is a 
reasonable choice for an alternative adenoviral vaccine vector to diminish the impact of 
antivector immunity. Therefore, as additional safety data emerge from studies exploring 
alternative adenoviral vectors in different global contexts, rAd35 should be considered for 
use as a vaccine delivery vector, particularly as effective antigen designs become available. 
This is particularly relevant when CD8+ T cell-mediated immunity is desirable in addition to 
antibody-based immunity, in subjects already primed with the antigens expressed by the 
rAd35 vector, and in settings with a high prevalence of preexisting immunity to Ad5, such 
as in sub-Saharan Africa.
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Figure 1. 
Safety assessment, showing maximum local reactogenicity A) and systemic reactogenicity, 
B) by treatment group. Subjects in control (C) groups 1-4 received group phosphate buffered 
saline. Subjects in treatment groups 1-3 (T1-T3) were Ad5 seronegative at baseline and 
received: T1- recombinant Ad35 (rAd35) prime and rAd5 boost; T2- three DNA priming 
injections boosted by rAd5; and T3- three DNA priming injections boosted by rAd35. 
Subjects in T4 were Ad5 seropositive at baseline and received three DNA priming injections 
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boosted by rAd35. P values for comparisons of local and systemic reactogenicity were 
determined using the Kruskal-Wallis test.
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Figure 2. 
Binding antibody net responses to Clades A (OOMSA 4076 gp140), B (B.con.env03 
140CF), and C (C.con.env03 140CF) isolates 4 weeks after the boost vaccination as 
measured by median fluorescence intensity (MFI)-Blank where ‘Blank’ is a sample specific 
background measure. Responders are shown in red circles and non-responders in blue 
triangles. Box plots display the distribution of positive responses for the vaccinees for each 
antigen. P-values are derived from Lachenbruch's test comparing rAd5 and rAd35 boosted 
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groups in Ad5 seronegative individuals and the Ad35-boosted group in Ad5 seropositive 
individuals.
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Figure 3. 
Binding antibody net responses to A) gp70 V1/V2 (Case A2) used in the RV144 trial and B) 
gp70 V1/V2 (A), the V1V2 antigen contained in the VRC A vaccine strain 4 weeks after the 
boost vaccination as measured by median fluorescence intensity (MFI)-Blank where ‘Blank’ 
is a sample specific background measure. Responders are shown in red circles and non-
responders in blue triangles. Box plots display the distribution of positive responses for the 
vaccinees for each antigen. P-values are derived from Lachenbruch's test comparing rAd5 
and rAd35 boosted groups in Ad5 seronegative individuals and the Ad35-boosted group in 
Ad5 seropositive individuals.
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Figure 4. HIV-specific CD4+ and CD8+ T-cell responses
The percentage of CD4+ (panel A) and CD8+ (panel B) T cells producing γ-interferon (IFN- 
γ) and/or interleukin-2 (IL-2) in response to EnvA matched peptide pools 4 weeks after the 
priming immunization(s) and 4 weeks after the boost as measured by intracellular cytokine 
staining. Responders are shown in red circles and non-responders in blue triangles. Boxplots 
show the distribution of the magnitude of response in positive responders only. The box 
indicates the median and interquartile range (IQR); whiskers extend to the furthest point 
within 1.5 times the IQR from the upper or lower quartile. Numbers at the top of each panel 
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show the number of responders / number with an assay result and the percent with positive 
response. P-values are derived from Lachenbruch's test comparing rAd5 and rAd35 boosted 
groups in Ad5 seronegative individuals and the Ad35-boosted group in Ad5 seropositive 
individuals. Data from samples with high background cytokine secretion was filtered, 
leading to differences in the number of samples with available data for CD4+ and CD8+ T 
cells.
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Figure 5. Vaccine-induced HIV-specific CD4+ and CD8+ T cells expressing multiple functional 
markers
The proportion of HIV-specific CD4+ (left) or CD8+ (right) T cells with one, two, three or 
four functions measured by expression of Granzyme B, IFN-g, IL-2, or TNFα is shown for 
positive responders from Figure 4. Boxplots show the distribution of responses; the box 
indicates the median and IQR, whiskers extend to the furthest point within 1.5 times the IQR 
from the upper or lower quartile.
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Table 1
HVTN 077 Protocol Schema.
Treatment Group Ad5 nAb* N**
Injection schedule months (days)
0 (0) 1 (28) 2 (56) 6 (168)
1 <18 34/6 rAd5 - - rAd5
2 <18 48/8 DNA DNA DNA rAd5
3 <18 48/8 DNA DNA DNA rAd35
4 ≥18 34/6 DNA DNA DNA rAd35
Total 192
164/28
DNA vaccinations were delivered by Biojector, and adenovectors were delivered by needle and syringe. Groups 2 and 3 were blinded to 
assignment to these groups.
*Adenovirus 5 (Ad5) neutralizing antibody (nAb) ≥ 18 represents Ad5 seropositive individuals;
**N represents the active vaccinees/placebo recipients who were blinded to treatment assignment within each treatment group.
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Table 2
Frequency and titers of neutralizing antibody to Ad5 and Ad35 among those screening for trial eligibility.
Ad5 Ad35
Titer N Frequency Titer N Frequency
<18 431 59.7% <12 670 91%
18-100 40 5.5% 12-100 38 5.2%
101-1000 156 21.6% 101-1000 14 1.9%
1001-4608 80 11.1% 1001-8748 13 1.7%
>4608 15 2.1% >8748 1 0.20%
Total* 722 100% Total 736 100%
*Ad5 neutralizing antibody titers were unavailable for fourteen individuals who underwent Ad35 neutralizing antibody screening.
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